- Home
- DAWN vs LDP Comparison
DAWN vs LDP Comparison
Compare DAWN & LDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DAWN | LDP |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 624.8M | 628.4M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | DAWN | LDP |
|---|---|---|
| Price | $7.97 | $21.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $26.56 | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 102.5K |
| Earning Date | 11-04-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.91% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $133,672,000.00 | N/A |
| Revenue This Year | $15.51 | N/A |
| Revenue Next Year | $49.99 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 31.11 | N/A |
| 52 Week Low | $5.64 | $16.16 |
| 52 Week High | $13.92 | $20.30 |
Technical Indicators
Market Signals| Indicator | DAWN | LDP |
|---|---|---|
| Relative Strength Index (RSI) | 42.36 | 52.30 |
| Support Level | $8.16 | $21.15 |
| Resistance Level | $8.60 | $21.50 |
| Average True Range (ATR) | 0.54 | 0.19 |
| MACD | -0.17 | 0.03 |
| Stochastic Oscillator | 2.16 | 90.54 |
Price Performance
Historical ComparisonAbout DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About LDP Cohen & Steers Limited Duration Preferred and Income Fund Inc.
Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. is a diversified, closed-end management investment company. Its primary investment objective is high current income and capital appreciation is its secondary investment objective. The Fund invests at least its managed assets in preferred and other income securities issued by U.S. and non-U.S. companies under normal market conditions.